Literature DB >> 1064876

Isolation from patients with breast cancer of antibodies specific for antigens associated with breast cancer and other malignant diseases.

Y Gorsky, F Vanky, D Sulitzeanu.   

Abstract

Antibodies were specifically purified, with the use of pleural fluid antigens entrapped in a polyacrylamide gel as immunoadsorbent, from a pool of sera from patients with breast cancer and from the pleural effusion of an individual patient. The purified antibodies were radioiodinated and tested for capacity to bind to the pleural fluid adsorbent. Binding of the radiolabeled antibodies was inhibited by many of the sera from women with breast cancer to a much greater extent than by sera of healthy women. With purified antibodies originating from the serum, 52% of the breast cancer sera and 16% of sera from patients with other malignancies were more inhibitory than were 95% of the sera of healthy women. In the tests with antibodies eluted from pleural fluid, 24% of the breast cancer sera and 25% of the sera from patients with other neoplastic diseases were more inhibitory than were 95% of the normal sera. We concluded that sera of patients with breast cancer may contain antibodies against antigens associated with breast cancer as well as additional antibodies against antigens that are also found in patients with other neoplastic diseases or in normal individuals. Individual breast cancer sera may inhibit binding of the labeled antibodies against breast cancer owing to their content of antibodies, antigen(s), or both.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1064876      PMCID: PMC430457          DOI: 10.1073/pnas.73.6.2101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  9 in total

1.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

Authors:  F C GREENWOOD; W M HUNTER; J S GLOVER
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

2.  Fluorescent antibody studies of human breast cancer.

Authors:  E M Edynak; Y Hirshaut; M Bernhard; G Trempe
Journal:  J Natl Cancer Inst       Date:  1972-04       Impact factor: 13.506

3.  Antibody studies of sera from patients with breast cancer.

Authors:  N C Estes; P A Morse; L J Humphrey
Journal:  Surg Forum       Date:  1974

4.  Antigenic changes in human breast neoplasia.

Authors:  E M Edynak; M P Lardis; M Vrana
Journal:  Cancer       Date:  1971-12       Impact factor: 6.860

5.  Immunofluorescence studies on sera of patients with breast carcinoma.

Authors:  E S Priori; G Seman; L Dmochowski; H S Gallager; D E Anderson
Journal:  Cancer       Date:  1971-12       Impact factor: 6.860

6.  The cross-linking of proteins with glutaraldehyde and its use for the preparation of immunoadsorbents.

Authors:  S Avrameas; T Ternynck
Journal:  Immunochemistry       Date:  1969-01

7.  Cell-mediated and humoral immune reactions to human tumours.

Authors:  R W Baldwin; M J Embleton; J S Jones; M J Langman
Journal:  Int J Cancer       Date:  1973-07-15       Impact factor: 7.396

8.  Immune responses to tumour and embryo cells in patients with mammary carcinoma.

Authors:  G Della Porta; S Canevari; G Fossati
Journal:  Br J Cancer Suppl       Date:  1973-08

9.  A radioactive antibody binding-inhibition assay, for the detection of cell-membrane related antigens in body fluids.

Authors:  Y Gorsky; D Sulitzeanu
Journal:  J Immunol Methods       Date:  1975-01       Impact factor: 2.303

  9 in total
  4 in total

1.  Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies.

Authors:  E Barbera-Guillem; K F May; J K Nyhus; M B Nelson
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

2.  Quantitation of human mammary epithelial antigens in cells cultured from normal and cancerous breast tissues.

Authors:  M Sasaki; J A Peterson; R L Ceriani
Journal:  In Vitro       Date:  1981-02

3.  Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.

Authors:  A Nicolini; C Colombini; L Luciani; A Carpi; L Giuliani
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

4.  Analysis of heteroantisera to cells from human malignant effusions by immunofluorescence and protein A binding.

Authors:  J P Birchall; J J Owen; B S Owen
Journal:  Br J Cancer       Date:  1977-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.